Immutep receives €1.36 million French R&D tax payment
Immutep (ASX:IMM; NASDAQ:IMMP) received €1.36M (A$2.16M) from France's R&D tax incentive program for 2025 activities. The company also received A$0.86M from Australia's R&D Tax Incentive. Funds will support R&D for eftilagimod alfa and IMP761. Immutep expects cash to last into early 2028.
How this was made
The 30-second read
Why it matters
The disclosed French R&D tax payment adds to non-dilutive cash and reinforces the company’s stated runway into 1H 2028, potentially lowering near-term financing anxiety.
Market read
A specific, non-dilutive cash inflow from France supports cash runway expectations, but it is not a direct clinical or regulatory catalyst.
What to watch
Investors may focus more on whether future eligible R&D levels remain consistent and whether other jurisdictions’ incentives (Australia, Germany) continue at similar magnitudes.
Background
Immutep is a clinical-stage immunotherapy company that relies on non-dilutive incentives across multiple countries to support R&D spending.
Ticker impact
Immutep says it received a €1.36 million French Crédit d’Impôt Recherche payment covering eligible 2025 R&D, non-dilutive funding for eftilagimod alfa and IMP761.
Likely mild support as investors factor incremental non-dilutive cash into the company’s funding runway.
The article provides a specific cash amount and ties it to 2025 eligible R&D and stated cash reach into 1H 2028, which can reduce financing risk. However, it does not change trial outcomes, approvals, or guidance beyond reinforcing runway.
Market effects
Highlights how biotech R&D tax incentives can materially affect cash runway for clinical-stage immunotherapy firms.
Adds incremental European (France) non-dilutive funding visibility for an ASX/Nasdaq-listed biotech.
Limited spillover; primarily company-specific cash management rather than a sector-wide policy shift.
Counterpoint
Tax-credit receipts may be lumpy and partially offset by ongoing R&D burn, so the market may discount the impact versus trial-driven catalysts.
Key entities
- companyImmutep Limited
Clinical-stage immunotherapy company receiving French R&D tax incentive cash for 2025 eligible research.
- programCrédit d’Impôt Recherche (France)
French research tax incentive that refunds a portion of eligible R&D expenditure.
- product_candidateeftilagimod alfa
Immutep product candidate funded by the non-dilutive incentive proceeds.
- product_candidateIMP761
Immutep product candidate funded by the non-dilutive incentive proceeds.
